ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen: FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

DOW JONES NEWSWIRES Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones. According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem. "We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development. Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million. A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful. Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months. Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
03/28/201512:03:025 Freakishly Expensive Cancer Drugs
03/28/201508:02:02Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
03/26/201521:09:30Portfolio Changes For The First Quarter Of 2015
03/26/201516:01:00Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From...
03/23/201520:21:07Amgen Is The Stock Of The Week
03/23/201517:44:29This Market Could Grow 6250% in 10 Years
03/23/201515:25:55Why ImmunoGen Inc. is Soaring Higher Today
03/23/201512:25:04Why ImmunoGen Inc. is Soaring Higher Today
03/23/201512:14:41Why ImmunoGen, Inc. is Soaring Higher Today
03/23/201510:14:03This Market Could Grow 6250% in 10 Years
03/23/201509:00:00Amgen To Webcast Investor Call At the 73rd Annual Meeting of...
03/23/201507:30:40Biogen Idec shortens name; CEO says drug candidates in neurodegenerative...
03/21/201512:04:06Dividend Stocks: 2 to Avoid, 1 to Buy
03/21/201511:02:02Drug Spending Is Soaring: 3 Takeaways You Can't Miss
03/20/201509:00:00Amgen Submits Application For Investigational LDL Cholesterol-Lowering...
03/20/201507:56:19Court rejects Amgen's bid to block Neupogen biosimilar
03/20/201507:29:07The Market Has Got It Wrong - Cramer's Mad Money (3/19/15)
03/20/201506:42:59Does Esperion Have An Ace Up Its Sleeve?
03/19/201518:46:14Judge Denies Amgen's Request to Block Novartis's Biosimilar of...
03/19/201516:03:02Can This Biotech Stock Go from Good to Great?

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad